Telios Pharmaincis A Clinical Stage Biopharmaceutical Company Based In Redwood Citycaliforniaspecializing In Developing Therapies For Mast Cell Mediated Inflammatory Diseasesfounded In 1993The Company Focuses On Small Molecule Drugs And Has A Team Of 51 To 100 Employeesits Annual Revenue Is Estimated Between $10 Million And $25 Million The Company S Pipeline Includes Innovative Brutonae S Tyrosine Kinasebtkinhibitorsnotable Candidates Are Tl 925A Topical Eye Drop For Dry Eye Disease Currently In Phase 2 Trialsand M 7583An Oral Btk Inhibitor For Primary Myelofibrosistl 925 Has Shown Promising Resultsproviding Rapid Relief From Symptoms And Significant Improvements In Clinical Measurestelios Pharma Aims To Address Significant Unmet Needs In Both Dry Eye Disease And Myelofibrosistargeting Markets With Limited Existing Therapies
